...
首页> 外文期刊>Basic & clinical pharmacology & toxicology. >Differences in preventing new-onset cardiovascular events with statin therapy in seniors aged 75 years and over: A cohort study in the South Korean National Health Insurance Database
【24h】

Differences in preventing new-onset cardiovascular events with statin therapy in seniors aged 75 years and over: A cohort study in the South Korean National Health Insurance Database

机译:在75岁及以上的老年人中预防他汀类药物治疗的新疾病心血管事件的差异:韩国国家健康保险数据库的队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this cohort study was to compare the effectiveness of statin regimens for primary prevention among seniors aged >= 75 years. Seniors aged 75-100 years for whom statin therapies for primary prevention were newly initiated between 1 January 2009 and 31 December 2011, and who continued the same statin regimen during the first year after the index date were identified using the claims data from the South Korean National Health Insurance Database. A propensity score matching and multivariable Cox proportional hazards model were developed to evaluate adjusted ischaemic cardiovascular-cerebrovascular event (CCE) risk and all-cause mortality risk for all patients, as well as for subgroups. A total of 5629 older patients aged 75-100 years were included in the study population. Compared to moderate-intensity statin therapy, low-intensity statin therapy was significantly associated with increased risk of ischaemic CCEs, while high-intensity statin therapy was associated with reduced risk of ischaemic CCEs; however, compared to moderate-intensity statin therapy, both low-intensity and high-intensity statin therapies were associated with increased risk of all-cause mortality. For the 4689 older patients who regularly received moderate-intensity statin therapy including 10 mg atorvastatin, 20 mg atorvastatin, 10 mg rosuvastatin or 20 mg simvastatin for primary prevention, multivariable regression adjusting for potential covariates revealed no significant difference in ischaemic CCEs or all-cause mortality between the moderate-intensity statin users and 10 mg atorvastatin users both before and after propensity scoring matching. No significant heterogeneity was detected in the patient subgroups. The results of this study based on real-world data can supply evidence-based reasons for choice of statin regimen for the primary prevention of CCEs in older people aged >= 75 years.
机译:该队列研究的目的是比较他汀类药物方案的初级预防方案的有效性,老年人= 75岁。年龄在2009年1月1日至2011年12月31日至12月31日之间进行了新发起的75-100岁的老年人,并在使用韩国索赔数据确定指数日期后的第一年继续相同的他汀类药物方案国家健康保险数据库。开发了一种倾向得分和多变量的Cox比例危害模型,以评估所有患者以及亚组的调整后的缺血性心血管 - 脑血管事件(CCE)风险以及全导致的死亡率风险。研究人群中共有5629岁75-100岁的老年患者。与中等强度汀类药物治疗相比,低强度肠梗理治疗与缺血CCE的风险显着相关,而高强度肠疗法与缺血CCE的风险降低有关;然而,与中等强度汀类药物治疗相比,低强度和高强度汀类药蛋白疗法与全导致死亡率的风险增加有关。对于4689名经常接受中等强度汀类药物治疗的老年患者,包括10mg阿托伐他汀,20毫克阿托伐他汀,10毫克罗苏伐他汀或20毫克辛伐他汀的初级预防,对潜在协变量的多变量回归调整缺血性CCE或全部原因没有显着差异中等强度汀类药物和10mg阿托伐他汀用户之间的死亡率均在倾向和倾向匹配之前和之后。在患者亚组中没有检测到显着的异质性。本研究的结果基于现实世界数据可以提供基于证据的原因,以便选择他汀类药物方案,以便预防老年人= 75岁。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号